Scholarlink

<p>Rare diseases (RDs) pose unique challenges to global healthcare. The European Union has led numerous initiatives, including EURORDIS, European Reference Networks (ERNs), and recently, the European Rare Diseases Research Alliance (ERDERA), to advance research, diagnosis, and treatment in this field. A crucial aspect of ERDERA is the strategic involvement of underrepresented countries (UCs), acknowledging their unique contributions to RD research and capacity building.</p><p>This paper takes Morocco as a case study to explore the scientific and translational benefits that UCs bring to ERDERA. With high rates of consanguinity, large groups of untreated patients, and the emergence of specific or novel mutations, these countries are positioned as key allies in discovering pathogenic variants, creating therapeutic targets, and enhancing precision diagnostics. We argue that integrating UCs into RD research frameworks not only strengthens the scientific ecosystem but also promotes equity, capacity development, and mutual benefit across regions.</p><p>Our findings support a shift toward inclusive and internationally coordinated strategies, emphasizing that the success of RD initiatives such as ERDERA depends on leveraging global diversity and fostering North–South collaborations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The involvement of underrepresented countries in the European rare diseases research alliance: Morocco’s assets

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Naima Fdil

摘要

Rare diseases (RDs) pose unique challenges to global healthcare. The European Union has led numerous initiatives, including EURORDIS, European Reference Networks (ERNs), and recently, the European Rare Diseases Research Alliance (ERDERA), to advance research, diagnosis, and treatment in this field. A crucial aspect of ERDERA is the strategic involvement of underrepresented countries (UCs), acknowledging their unique contributions to RD research and capacity building.

This paper takes Morocco as a case study to explore the scientific and translational benefits that UCs bring to ERDERA. With high rates of consanguinity, large groups of untreated patients, and the emergence of specific or novel mutations, these countries are positioned as key allies in discovering pathogenic variants, creating therapeutic targets, and enhancing precision diagnostics. We argue that integrating UCs into RD research frameworks not only strengthens the scientific ecosystem but also promotes equity, capacity development, and mutual benefit across regions.

Our findings support a shift toward inclusive and internationally coordinated strategies, emphasizing that the success of RD initiatives such as ERDERA depends on leveraging global diversity and fostering North–South collaborations.